Orchestra BioMed Holdings, Inc. (OBIO) research

Orchestra BioMed Holdings, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$6.08
As of

Orchestra BioMed Holdings, Inc. (OBIO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.

As of . Source: SEC EDGAR filings for OBIO. Method and limitations.

SHARE THIS CARD

Share the OBIO intelligence card

A branded snapshot of OBIO: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion OBIO intelligence card preview
Post to X
LIVE TERMINAL

See OBIO live in the terminal

Track OBIO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live OBIO terminal, free

Active signals for OBIO

FREE, NO ACCOUNT

Every signal on OBIO, as it fires

You are seeing 5 of 10 signals recorded on OBIO since 2026-06-03.

The five above landed across 2 days. The other 5 were recorded on 1 other days. 7 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in OBIO (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 68572M106 · 2026Q2$388K0.00%,
CITADEL ADVISORS LLCCUSIP 68572M106 · 2026Q2$242K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 68572M106 · 2026Q2$97K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, OBIO

OBIO against its peers

OBIO's operating margin of -154.7% ranks in the 50th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.

MetricOBIOPeer medianPercentilen
Revenue FY33.5M USD31.4M USD5317
Operating margin-154.7%-201.0%5014
Net margin-157.4%-155.9%5014
Return on equity-98.4%-33.6%2120

Peers (24): OCGN, XFOR, ENTA, DMAC, RCKT, EBS, MYGN, LXEO, CMPX, BBOT, FENC, EVMN, BNTC, IPSC, PRLD, STRO, EYPT, PROK, LRMR, SION, SABS, QTTB, ABEO, GALT. Left out: RZLT (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more OBIO signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to OBIOand get the insider, 13F, options, and confluence read in one view.

Open the live OBIO terminal, free